How much funding has Sonoma Biotherapeutics raised?

Sonoma Biotherapeutics has raised $410.0M in total funding, most recently a Series B round.

Who are Sonoma Biotherapeutics's investors?

Sonoma Biotherapeutics's investors include Regeneron Pharmaceuticals, GV, ARCH Venture Partners, 8VC, JDRF T1D Fund, Lyell Immunopharma.

When was Sonoma Biotherapeutics founded?

Sonoma Biotherapeutics was founded in 2019.

Where is Sonoma Biotherapeutics headquartered?

Sonoma Biotherapeutics is headquartered in Seattle, Washington, United States.

What industry is Sonoma Biotherapeutics in?

Sonoma Biotherapeutics operates in Biotech, Life Sciences, Therapeutics.

How many employees does Sonoma Biotherapeutics have?

Sonoma Biotherapeutics has 51-200 employees.

Sonoma Biotherapeutics

Seattle, United States · Founded 2019 · $410.0M raised

Biotech

Life Sciences

Therapeutics

Headquarters: Seattle, Washington
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: sonomabio.com
Total Funding: $410.0M
Last Round: $75.0M Series BSep 2024
Rounds: 7

About

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company uses proprietary platform technologies to engineer targeted, durable Treg cell therapies. Its lead program targets rheumatoid arthritis, with additional indications in development through a collaboration with Regeneron.

Summary

Sonoma Biotherapeutics is a Biotech company based in Seattle, United States, founded in 2019. It has raised $410.0M in total across 7 rounds, most recently a $75.0M Series B round in Sep 2024. Investors include Regeneron Pharmaceuticals, GV and ARCH Venture Partners.

LinkedIn X (Twitter)